Results 11 to 20 of about 219,878 (216)

Novel Delivery Systems for Checkpoint Inhibitors

Medicines, 2019
Checkpoint inhibition (CPI) therapies have been proven to be powerful clinical tools in treating cancers. FDA approvals and ongoing clinical development of checkpoint inhibitors for treatment of various cancers highlight the immense potential of ...
Purushottam Lamichhane, Rahul Deshmukh, Julie A. Brown, Silvia Jakubski, Priyanka Parajuli, Todd Nolan, Dewan Raja, Mary Badawy, Thomas Yoon, Mark Zmiyiwsky, Narottam Lamichhane   +10 more
doaj   +1 more source

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

Frontiers in Oncology, 2020
The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity.
S. Morteza Seyed Jafari, Laurence Feldmeyer, Robert E. Hunger   +2 more
doaj   +1 more source

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Frontiers in Cell and Developmental Biology, 2020
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung   +3 more
doaj   +1 more source

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Cancer Biology & Medicine, 2015
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis, Richard Skelton, Lei Zheng   +2 more
doaj   +1 more source

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

Melanoma Management, 2019
Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status.
Shweta Shah, Leon Raskin, David Cohan, Omid Hamid, Morganna L Freeman   +4 more
doaj   +1 more source

The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]

Клиническая практика
The incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina, Aisylu N. Bagautdinova, Milyausha M. Zinatullina, NIkita A. Gorbunov, Elvina T. Zainetdinova, Diana I. Bukharmetova, Daniil Yu. Leonov, Aibike G. Pirmagomedova, Anna E. Chernyshova, Maria P. Markhanos, Anna G. Abgaryan, Arina S. Arustamyan, Konstantin S. Chavro, Farzonakhon Mirzojonova   +13 more
doaj   +1 more source

Research Progress of Immune Checkpoint Therapy on Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2021
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj   +1 more source

Checkpoint inhibitors in ovarian cancer: A review of preclinical data

Gynecologic Oncology Reports, 2019
Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with ...
David W. Doo, Lyse A. Norian, Rebecca C. Arend   +2 more
doaj   +1 more source